Eli Lilly (NYSE:LLY) and commercialization partner Boehringer Ingelheim announce positive results from a Phase 3 clinical trial, EMPEROR-Reduced, evaluating type 2 diabetes med Jardiance (empagliflozin) 10 mg in patients with chronic heart failure with reduced ejection fraction with or without diabetes.
The study met the primary endpoint demonstrating a statistically significant relative reduction in the composite of cardiovascular death or hospitalization due to heart failure, when added to standard-of-care treatment, compared to placebo.
Complete results will be presented virtually at the European Society of Cardiology Congress in late August.
Another Phase 3, EMPEROR-Preserved, assessing Jardiance in adults with heart failure with preserved ejection fraction, is in process with topline data expected in 2021.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.